UNASSIGNED: 4152 Background: @entity356 is commonly treated with TS1-based chemotherapy, but a subsequent treatment method is necessary for @entity1 disease relapse*recurrence. In this study we investigated the safety of combination of @entity1205 [ @entity1205 (T)] with TS1 in such @entity1 . METHODS: Nine @entity1 with unresectable or relapsed @entity356 came to the hospital every 2 weeks. They were allocated to 3 treatment groups. TS1 was administered according to the usual schedule, while T was administered in a dosage of 25, 30 or 35 mg/m(2) every two weeks. The @entity1 were monitored for adverse reactions. RESULTS: No adverse reactions of grade 3 or greater severity occurred in the @entity1 groups administered T at 25 or 30 mg/m(2), but they did manifest in 2 of the 3 @entity1 administered T at 35 mg/m(2). In some @entity1 with adverse reactions, the reactions were strong even after the dosage of T was reduced, but reduction of the dosage of TS1 was effective in alleviating the symptoms. CONCLUSIONS: The recommended dosage of T when administered concurrently with the usual TS1 dosage is 30 mg/m(2). In addition, reduction of the TS1 dosage is effective for alleviating intolerable adverse reactions to the concurrent chemotherapy. No significant financial relationships to disclose.

Phase I study of concurrent therapy using TS1 and XXXX for @entity356 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel', 'Taxotere'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'Gastric cancer']
@entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']
